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Established Facts
• Accurate and systematic mediastinal lymph node staging through endobronchial ultrasound (EBUS) 
transbronchial needle aspiration is important for the diagnosis and decision of treatment strategy in 
lung cancer. In order to predict malignancy in lymph nodes, ultrasound characteristics can be used in 
adjunct to PET and CT characteristics. A new ultrasound technique termed strain elastography (SE) 
has become available in EBUS and measures tissue elasticity. However, the elastography assessment 
lacks standardization.
Novel Insights
• We systematically compared different EBUS-SE assessment strategies in patients with lung cancer and 
show that the mean strain histogram technique is the most robust, objective, and reproducible tech-
nique. Applied in daily clinical practice, adding the EBUS-SE histogram mean has a clear additional 
predictive value in both imaging suspicious and imaging normal lymph nodes, with stiffer lymph nodes 
being more likely malignant. These findings could be of potential value to better select patients for ad-
ditional surgical staging procedures.
DOI: 10.1159/000494143
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Abstract
Background: In lung cancer staging, mediastinal lymph 
nodes are currently aspirated using endobronchial ultra-
sound transbronchial needle aspiration (EBUS-TBNA) based 
on size and FDG-PET avidity. EBUS strain elastography (SE) is 
a new technique that may help predict the presence of ma-
lignancy. However, a standardized assessment strategy for 
EBUS-SE measurement is lacking. Objectives: The aim of this 
study was to determine the optimal assessment strategy for 
investigating the predictive value of EBUS-SE in mediastinal 
lymph nodes. Methods: Two qualitative visual analogue 
scale strain scores and two semiquantitative strain elastog-
raphy measurements (a strain histogram and strain ratio) 
were acquired in 120 lymph nodes of 63 patients with (sus-
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pected) lung cancer. The dataset was randomized into an 
80% training dataset to determine cut-off values. Perfor-
mance was consecutively tested on the remaining 20% and 
the overall dataset. Results: The semiquantitative mean his-
togram scoring strategy with a cut-off value of 78 (range 
0–255) showed the best and most reproducible performance 
in prediction of malignancy with 93% overall sensitivity, 75% 
specificity, 69% positive predictive value, 95% negative pre-
dictive value, and 82% accuracy. Combining the EBUS-SE 
mean histogram scoring outcome with PET-CT information 
increased the post-test probability of disease in relevant clin-
ical scenarios, having a positive test likelihood ratio of 4.16 
(95% CI 2.98–8.13) and a negative test likelihood ratio of 0.14 
(95% CI 0.04–2.81) in suspicious lymph nodes based on FDG-
PET or CT imaging. Conclusions: EBUS-SE can potentially 
help predict lymph node malignancy in patients with lung 
cancer. The best semiquantitative assessment method is the 
mean strain histogram technique. © 2018 The Author(s)
Published by S. Karger AG, Basel
Introduction
Endobronchial ultrasound transbronchial needle aspi-
ration (EBUS-TBNA) has evolved from a diagnostic pro-
cedure to a staging procedure, and is now recommended 
as the first-line staging procedure in lung cancer [1, 2]. 
For accurate and complete staging, it is imperative that 
the endoscopist performs a full and systematic evaluation 
of the entire mediastinum. The evaluation should start in 
the contralateral hilum and proceed to the ipsilateral hi-
lum, and preferably combine EBUS evaluation with 
esophageal ultrasound evaluation using the EBUS scope 
(EUSb) [1]. The goal of EBUS has herein shifted from the 
confirmation of metastatic disease to proving the absence 
of metastatic disease. Besides the available CT and FDG-
PET information, ultrasound characteristics are often 
used for selecting nodes to aspirate in daily clinical prac-
tice. A study by Fujiwara et al. [3] introduced the B-mode 
ultrasound characteristics of round shape, distinct lymph 
node margins, heterogeneous echogenicity, and presence 
of a central necrosis sign as independent predictive mark-
ers for malignancy. Later however, Evison et al. [4] 
showed that heterogeneous echogenicity was the only sig-
nificant predictor of malignancy. Several other studies 
also found discording results in using these ultrasound 
features [5–7], resulting in limited widespread diagnostic 
application of these echo characteristics [8].
Additional tools like ultrasound strain elastography 
(SE) have become available that may help predict the 
probability of malignancy in mediastinal lymph nodes. 
Ultrasound SE visualizes relative tissue stiffness by mea-
suring axial tissue deformation. In EBUS-TBNA specifi-
cally, the periodical motion of the heart and greater ves-
sels cause tissue deformation. Monitoring this tissue de-
formation by means of ultrasound over time enables a 
derivation of relative tissue strain which is a marker of 
tissue stiffness. A region of tissue that is heavily deformed 
over time when compared to another region in the same 
image is relatively soft (and thus high in strain). A region 
that is barely deformed by this same deformation force is 
in contrast relatively stiff (and thus low in strain). In ul-
trasound SE, the received signal intensities over time are 
correlated to one another for quantifying these deforma-
tions. As current ultrasound technology only allows ac-
curate cross-correlation of signal intensity along the 
propagation direction of ultrasound itself, it should be 
acknowledged that it is primarily an axial measurement 
of strain (for more information, also refer to the online 
supplementary material; for all online suppl. material, see 
www.karger.com/doi/10.1159/000494143). Ultrasound 
SE has already shown value in differentiating benign from 
malignant lesions in the thyroid and breast, where an ex-
ternal force can be used and standardized [9–12]. Several 
pilot studies now report that endoscopic ultrasound SE 
can also be used for differentiating malignant and benign 
lymph nodes in the mediastinum with high accuracy, 
with lesions low in strain being more likely malignant 
[13–20]. However, the optimal method for scoring the 
presentation of the SE values in EBUS applications re-
mains unclear [21]. Several qualitative and semiquantita-
tive techniques have been reported so far. For qualitative 
presentation of strain, visual analogue scale (VAS) scor-
ing techniques can be used. This is done by converting 
calculated relative strain into a color gradient and super-
imposing it on the B-mode image. This strain color image 
is then used for scoring the lymph node region of interest 
upon its major color component [14, 17, 18, 22] or pat-
tern-color combination [12]. Another frequently report-
ed method is the semiquantitative strain ratio measure-
ment [17, 19, 23]. This technique requires that the opera-
tor manually selects the lymph node region and a 
secondary surrounding tissue region. By doing so, a ratio 
of strain can be calculated [17, 19, 23, 24]. A third less fre-
quently used method is the semiquantitative strain histo-
gram scoring method. This method quantifies the relative 
strain found in a manually selected lymph node area, and 
presents this as a histogram of strain counts [25]. 
Ideally, every assessment is operator independent, 
swift, and safe. Yet in EBUS several factors will influence 
measurement results as a consequence of the technologi-
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cal principles used in SE (see online suppl. material). For 
example, the position of the target node in relation to the 
source of compression and the tip of the EBUS scope af-
fects the measured axial strain in EBUS-SE.
In this explorative study, we aim to determine the op-
timal EBUS-SE scoring and assessment strategy in pa-
tients with suspected or proven lung cancer. This is done 
by comparing the performance of predicting mediastinal 
lymph node malignancy among different scoring meth-
ods. We hypothesize that the strain histogram method 
will give the best overall predictive accuracy for diagnos-
ing the lymph node malignancy since this will be the most 
operator independent and thus objective technique. We 
furthermore hypothesize that EBUS-SE will increase the 
predictive value of mediastinal lymph node ultrasound 
imaging. To do so, we aim to explore what the clinical ef-
fect of adding EBUS-SE is on the probability of malig-
nancy in combination with FDG-PET and CT imaging.
Materials and Methods
All patients at the Radboud University Medical Center (Nijme-
gen, The Netherlands) who had an indication for a diagnostic or 
staging EBUS-TBNA procedure for suspicion of lung cancer were 
eligible and included. This study was conducted with approval of 
independent ethics committee as part of the E-predict multicenter 
study (NCT02488928) and all included patients gave informed 
consent. The inclusion period ranged from July 2015 to April 2016. 
All subjects had no history of prior radio- or chemotherapy and no 
general EBUS-TBNA contraindications. The EBUS-TBNA proce-
dure was performed according to local and international guide-
lines [1, 26]. Measurements were acquired using the Hitachi Prei-
rus Hi Vision processor (Hitachi Corp., Tokyo, Japan) with Hita-
chi Real-Time Elastography software in combination with Pentax 
EB-1970UK echo-endoscopes (Pentax Medical, Tokyo, Japan). 
The recommended diagnostic workup of our hospital was used; all 
nodes with a short-axis size > 10 mm on CT, ultrasound-based 
short axis size > 5 mm, or FDG-PET avid nodes in at least regions 
4L, 4R, and 7 were routinely aspirated. FDG-PET scans were ob-
tained and evaluated by the radiologist following the European 
Association of Nuclear Medicine guidelines [27]. While standard 
uptake values of individual lymph nodes were not routinely re-
ported, a cut-off of 2.5 was typically used. EBUS-SE measurement 
collection and assessment was performed using a standardized op-
erating protocol (online suppl. Fig. E.1.). In brief, real-time dual 
ultrasound B-mode and elastography imaging were used for data 
collection of both B-mode lymph node ultrasound characteristics 
(size, shape, margin, echogenicity, central hilar structure presence, 
and coagulation necrosis sign) and quantitative and qualitative 
EBUS-SE measurements. After these measurements, routine 
EBUS-TBNA sampling was performed under guidance of B-mode 
ultrasound alone. Cytology and consecutive histology (if available) 
of the EBUS-TBNA specimen combined with clinical follow-up 
were used as the gold standard for determining individual lymph 
node diagnosis.
EBUS-SE Evaluation Techniques
Qualitative Evaluation
For visual scoring of the strain, two VAS scoring methods 
based upon earlier reports were used [14, 17, 22]. The first VAS 
system requires the operator to classify the image into one of five 
groups based on the major color component. From low to high 
strain, respectively, these scores correspond to: 1, predominantly 
blue; 2, blue and green; 3, predominantly green; 4, green and red; 
5, predominantly red (Fig. 1).
The second qualitative VAS scoring method used a modified 
version of the Tsukuba score, a scoring system based on a combina-
tion of the visualized color and the pattern of the strain image. This 
scoring method has shown to be promising in the classification of 
breast lesions [12]. However, the scoring was slightly altered by the 
authors to accommodate for the differences in breast US and EBUS 
imaging. The operator grades the lymph node EBUS-SE image fol-
lowing a six-category classification system (Fig. 2).
Semiquantitative EBUS-SE Evaluation
For semiquantitative scoring of EBUS-SE, two measurement 
methods are evaluated (see online suppl. material). The first mea-
surement method is the mean SE histogram. This requires a (rectan-
gular) hand selection of a lymph node region of interest. After selec-
tion, strain values are computed from the selected area and relayed 
back to the operator through a histogram of strain counts (Fig. 1). 
The second semiquantitative scoring method is the strain ratio. 
Herein, the lymph node region of interest as selected during the 
strain histogram method are compared against a hand-selected sur-
rounding reference tissue area using the Matlab Image Processing 
Toolbox (version 9.1.0, MathWorks Inc., Natick, MA, USA; online 
suppl. Fig. E.2). As opposed to the other methods, the strain ratio was 
measured after completion of the EBUS procedure by one operator 
(R.L.J.V.) blinded for patient details and pathology outcome.
Statistics
The performance of the different EBUS-SE scoring techniques 
was evaluated by a priori randomizing the final dataset into an 80% 
training dataset for determining scoring method cut-off values and 
using the remaining 20% of data to test the scoring method perfor-
mance on unseen data. To evaluate the performance of the models, 
sensitivity, specificity, negative predictive value (NPV), positive 
predictive value (PPV), accuracy, negative and positive likelihood 
ratios, and post-test probability of malignancies (using the likeli-
hood ratios) with their respective 95% confidence intervals (CI) 
are calculated among the separate and combined datasets. Area 
under the curve (AUC) is calculated for continuous variables. 
To exploratively correlate SE imaging to outcome, pathology re-
sults were classified as malignant or benign. Patients diagnosed with 
granulomatous disease or patients for whom measurement data were 
incomplete were excluded from the final dataset before randomization 
and analysis (Fig. 3). The statistical computing language R and inter-
face R-studio (version 1.1.414) were used for statistical analysis [28]. 
Results
In total, 150 lymph node SE measurements were ob-
tained in 81 patients. After the exclusion of other patholo-
gies and incomplete measurements, 120 lymph nodes in 
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63 unique patients remained (Fig. 3). A total of 45 lymph 
nodes herein proved to be malignant based on EBUS- 
TBNA alone (43 lymph nodes, 28 patients) or by surgical 
follow-up of false negative benign EBUS-TBNA cytology 
findings (2 lymph nodes, 2 patients). For the 75 lymph 
nodes (42 unique patients) eventually classified as benign, 
follow-up data were available in 61 nodes (81.3%). Surgi-
cal proof of benign EBUS-TBNA findings was available in 
41 lymph nodes (55%) by either resection (15 nodes, 9 pa-
tients) or mediastinoscopy (26 nodes, 13 patients). Long-
term clinical follow-up was available in 20 lymph nodes 
(27%, 12 patients) with a median follow-up time of 23 
months (min.–max. 3–34). No follow-up of benign EBUS-
TBNA findings was available in 14 lymph nodes (19%, 9 
patients) due to rapid disease progression (6 nodes, 5 pa-
tients) and loss to follow-up (8 nodes, 4 patients). 
The general patient demographics and lymph node 
details are summarized in Table 1. The lymph nodes were 
a b
c d
Fig. 1. Typical examples of EBUS-SE imaging of 4L lymph nodes 
as captured by Hitachi Real-Time Strain Elastography software on 
the Preirus Hi Vision processor (Hitachi Corp. Tokyo, Japan) in 
combination with the Pentax UB-1970UK endoscope (Pentax 
Medical, Tokyo, Japan). In each panel on the left a conventional 
B-mode image with strain map overlay in color is seen; the grey 
box is the manually set region of interest (ROI) selection for calcu-
lation of the strain histogram mean. The different colors corre-
spond to measured relative strain. Red corresponds to high defor-
mation, green to intermediate measured deformation, and blue to 
relatively low deformation. On the right side of each panel, the 
B-mode image can be seen and used as a reference. In the bottom 
left of each panel a strain rate graph is shown, to be used for qual-
ity control and frame selection of elastography measurements. In 
the bottom right of each panel the strain histogram as calculated 
based on the selected ROI is also shown. Finally, the strain histo-
gram parameters are presented in the table at the bottom of each 
panel. All panels depict 4L lymph nodes: EUSb approach (a), 
EBUS approach (b–d). Malignant nodes (a, b), benign nodes 
(c, d). 
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Schematic
illustration Typical image Classification standard Score
Strain is seen in the entire hypoechoic area (the
entire lesion is shown in green similar to the
surrounding tissue)  
1
Strain is seen within most of the hypoechoic
area but some areas show no strain (the lesion
is a mixture of red, green, and blue)  
2
Strain appears only in the periphery, no strain
in the center of the lesion (center of the lesion
is blue, the periphery is green)  
3
No strain is measured within the lesion (the
entire lesion is shown in blue) 4
No strain is measured within the lesion nor in
the surrounding tissues (the lesion and the
surrounding tissues are blue)  
5
Typical artifact seen when blood vessels invade
the lymph node. Red in the center of the vessel
surrounding, green in the vicinity
X
Fig. 2. Modified Tsukuba score classifica-
tion system used for VAS scoring of lymph 
node EBUS-SE, adapted from Itoh et al. 
[12]. The depicted typical images are all 
EBUS-SE lymph node images obtained fol-
lowing the standard acquisition protocol 
described in the Methods section and on-
line supplementary material. The original 
Tsukuba scoring system as introduced for 
breast imaging was adjusted by the authors 
to accommodate for differences in endo-
bronchial and breast imaging [12].
Eligible patients with (suspected) lung cancer
(n = 150 lymph nodes, 81 patients)
Excluded (n = 30 lymph nodes, 18 patients)
- Granulomatous disease
(n = 18 lymph nodes, 8 patients)
- Incomplete data
(n = 12 lymph nodes, 10 patients)
Training dataset
(n = 100 lymph nodes, 38 malignancies)
Determining cut-offs of strain
elastography scores
Training dataset
(n = 20 lymph nodes, 7 malignancies)
Testing cut-offs for performance
on new data
Randomization
(n = 120 lymph nodes, 63 patients)
Enrolled
Follow-up
Analysis
Fig. 3. CONSORT flow diagram of the study design. 
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randomized into the training and test dataset (Fig. 3). The 
a priori-defined training dataset included 100 randomly 
selected lymph nodes. The remaining testing dataset con-
sisted of 20 lymph nodes. The prevalence of malignancy 
or pre-test probability of malignant disease in both data-
sets was approximately equal at 0.38 and 0.35, respective-
ly. The results of general B-mode ultrasound feature clas-
sification are presented in online supplementary Table 
E.1. In the final dataset, 79 of 120 lymph nodes (66%) 
were classified as FDG-PET positive. No PET scan was 
available in 3 patients (three lymph nodes), and no con-
trast CT was available in 1 patient (one lymph node). 
EBUS-SE Scoring Method Assessment Cut-Off Values
Cut-off values of all four SE scoring methods were first 
optimized by analyzing performance on the training da-
taset using accuracy, AUC (in the cases of strain histo-
gram and strain ratio scoring), and individual predictive 
values of sensitivity, specificity, NPV, and PPV. 
For the color VAS scoring system, optimal predictive 
performance was found if lymph nodes categorized as 
“predominantly blue” or “blue and green” were grouped 
together (predicting malignancy) versus all other catego-
ries grouped (predicting benign outcome, online suppl. 
Fig. E.3). 
The modified Tsukuba scoring method performed 
best when placing the cut-off at the two lowest of five 
scores (online suppl. Fig. E.4), grouping scores 4–5 as ma-
lignant and scores 1–3 as benign. For the semiquantita-
tive measurements, the ROC curve analysis of the strain 
histogram method (AUC 0.846, online suppl. Fig. E.5) 
showed a relative mean strain value of < 78 (range 0–255, 
with a lower value representing less strain) to be most 
predictive of malignancy using our software settings. The 
strain ratio was most predictive of malignancy when the 
mean of the lymph node strain divided by the reference 
tissue strain was more than 1.67 (AUC 0.637, online sup-
pl. Fig. E.5).
EBUS-SE Predictive Value
With the above-described cut-off values, the different 
predictive values as introduced in the Methods section 
were calculated on both datasets. The results are summa-
rized in Table 2, and the calculation of likelihood ratios 
are also presented in online supplementary Table E.2. The 
prospectively collected color VAS scoring, modified Tsu-
Table 1. Overall patient demographics and lymph node characterization
Demographics and characterization Measured lymph nodes 
region n (malignant/benign) % total
Study subjects, n 63 2L 1 (1/0) 0.8
Mean age, years 64.3 (41–83) 2R 2 (2/0) 1.6
Sex (male/female) 39 (61)/24 (39) 4L (EB) 23 (11/12) 19.2
4L (EUSb) 7 (4/3) 5.8
Aspirated lymph node characteristics 4R 25 (7/18) 20.8
CT size (SA), mm 11.95 (2–41) 7 (LMB) 3 (0/3) 2.5
FDG-PET avidity 79 FDG+/38 FDG–/3 NA 7 (RMB) 23 (4/19) 19.2
US size (SA), mm 9.95 (4–26) 7 (EUSb) 10 (5/5) 8.3
10L 0 (0/0) 0
Lymph node pathology outcome 10R 2 (1/1) 1.6
Benign 75 (62.5) 11L 10 (3/7) 8.3
Malignant 45 (37.5) 11R 14 (7/7) 11.7
NSCLC adenocarcinoma 19 (15.8)
NSCLC SqCC 15 (12.5)
NSCLC NOS 1 (0.8)
Small cell lung carcinoma 5 (4.2)
LCNEC 3 (2.5)
Invasive ductal carcinoma 2 (1.6)
Values are presented as the mean (range) or n (%). SA, short axis; NA, not available; NSCLC, non-small cell 
lung cancer; SqCC, squamous cell carcinoma; NOS, not otherwise specified; LCNEC, large cell neuroendocrine 
carcinoma; EB, endobronchial; EUSb, esophageal using EBUS scope; LMB, left main bronchus; RMB, right main 
bronchus.
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kuba scoring, and strain histogram scoring had similar 
accuracies in the training dataset of 76, 82, and 82%, re-
spectively. The most notable differences in individual 
performance factors among these methods were found in 
sensitivity and NPV. Sensitivity and NPV are upwards of 
76% in all three methods. However, fewer false negatives 
were found in the strain histogram method, having a sen-
sitivity of 92% and NPV of 94% (being 3–16% higher than 
the other two methods). Consequently, it also had the 
lowest negative post-test probability of malignancy in our 
dataset (0.06). Following the specificity and PPV, positive 
post-test probability of malignancy in our dataset seems 
to be similar in the three methods at around 0.70. While 
performance among the three prospective methods seems 
comparable, the strain ratio most markedly has lower 
sensitivity (50%) and NPV (73%) in the training dataset, 
which is further reflected by the lower accuracy (71%). 
When the cut-offs of the four scoring methods are 
consecutively used to analyze performance on the testing 
dataset, the accuracies remain within the earlier deter-
mined 95% CI of the training dataset (Table 2). However, 
the positive and negative post-test probability of malig-
nancy as based on the likelihood ratios (online suppl. Ta-
ble E.2) do show differences. All collected methods except 
the strain ratio showed no false negatives in the test data-
set. Consequently, both the color VAS score and modified 
Tsukuba score performed better than the 95% CI as 
determined from the training dataset. Furthermore, we 
would expect a higher than 0.58 positive post-test prob-
ability of malignancy of the modified Tsukuba scoring 
method based on the training dataset results (95% CI 
0.61–0.82). 
When combining performances of both the training 
and test dataset, the mean of the strain histogram is shown 
to best predict lymph node malignancy. It has the lowest 
negative post-test probability of malignancy while accu-
racy is similar to the best of the methods. The mean of the 
strain histogram furthermore shows similar performance 
when testing on new and unseen data. 
Effect of EBUS-SE on Probability of Malignancy 
Assessment
Based on the analysis of the different EBUS-SE scoring 
methods, the SE histogram mean scoring method was 
used to further investigate if EBUS-SE could be of poten-
tial added value in clinical workup. This was investigated 
Table 2. Summary of main EBUS-SE scoring method performance results
EBUS-SE scoring method Sens, % Spec, % PPV, % NPV, % Accuracy, %
(95% CI)
Positive post-test 
probability of 
malignancy (95% CI)
Negative post-test 
probability of 
malignancy (95% CI)
Training dataset (100 lymph nodes, 38 malignancies – pre-test probability of malignancy 0.38)
Color VAS score 76 77 67 84 77 (68–85) 0.67 (0.56–0.78) 0.16 (0.08–0.23)
Modified Tsukuba score 87 79 72 91 82 (73–89) 0.72 (0.61–0.82) 0.09 (0.03–0.16)
Strain histogram mean 92 76 70 94 82 (73–89) 0.70 (0.61–0.80) 0.06 (0.00–0.13)
Strain ratio 50 84 65 73 71 (61–80) 0.66 (0.50–0.80) 0.27 (0.20–0.33)
Test dataset (20 lymph nodes, 7 malignancies – pre-test probability of malignancy 0.35)
Color VAS score 100 69 64% 100 80 0.64 0.00*
Modified Tsukuba score 100 62 58 100 75 0.58* 0.00*
Strain histogram mean 100 69 64 100 80 0.64 0.00
Strain ratio 29 85 50 69 65 0.5 0.31
Overall dataset (120 lymph nodes, 45 malignancies – pre-test probability of malignancy 0.375)
Color VAS score 80 76 67 86 78 0.67 0.14
Modified Tsukuba score 89 76 69 92 81 0.69 0.08
Strain histogram mean 93 75 69 95 82 0.69 0.05
Strain ratio 47 84 64 72 70 0.64 0.28
Scoring method performance was obtained by randomly partitioning the total dataset into a training (80%) and test dataset (20%). 
The cut-off scores of the scoring methods are first determined by optimization of performance on the training dataset (online suppl. Fig. 
E.3–E.5). Transferability of performance using these scores is subsequently assessed in the test dataset. The post-test probabilities of 
malignancy are determined by the pre-test probability of malignancy and the likelihood ratios as defined in online supplementary Table 
E.2. * Denotes significant differences between training and test dataset, being outside the 95% CI as determined in the training dataset. 
Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; VAS, visual analog scale.
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by calculating the effect on the probability of malignancy 
when combined with PET-CT imaging information of 
both the abnormal and normal mediastinal lymph nodes 
in the overall dataset (Fig. 4; online suppl. Table E.2, E3). 
Based on available combined PET avidity and/or CT size 
> 10 mm, a group of normal (n = 26) and suspicious (n = 
90) mediastinal lymph nodes were identified in our com-
plete dataset. In these groups, the probability of malig-
nancy was 8 and 46%, respectively. Explorative analyses 
showed that the addition of EBUS-SE histogram scoring 
in the subgroup of suspicious lymph nodes increases the 
post-test probability of malignancy from 46 to 73% (pos-
itive likelihood ratio 4.61, 95% CI 2.98–8.13). Oppositely, 
a negative EBUS-SE histogram analysis in this group of 
suspicious nodes reduces the post-test probability of ma-
lignancy from 46 to 8% (negative likelihood ratio 0.143, 
95% CI 0.04–2.81; Fig. 4; online suppl. Table E.3). In the 
subgroup of imaging normal lymph nodes, a mean EBUS-
SE histogram < 78 increased the probability of malignan-
cy from 8 to 45%. If EBUS-SE outcome indicated non-
malignancy in the PET/CT negative lymph nodes, the 
probability of malignancy dropped from 8 to 0%, negat-
ing 2 cases where PET-CT imaging was found to be false 
negative (Fig. 4; online suppl. Table E.3). 
Discussion
EBUS-SE could potentially be a sensitive technique to 
help predict lymph node malignancy in patients with 
lung cancer. We found that the semiquantitative mean 
histogram scoring method with a cut-off value of 78 
(range 0–255) showed the best, most objective and most 
reproducible performance in the prediction of malignan-
cy with 93% overall sensitivity, 75% specificity, 69% PPV, 
95% NPV, and 82% accuracy. Exploratively combining 
relative lymph node stiffness by using the EBUS-SE his-
togram mean scoring outcome with CT and/or PET-CT 
information further increased confidence in post-test 
probability of disease, having a positive test likelihood ra-
tio of 4.16 (95% CI 2.98–8.13) and a negative test likeli-
hood ratio of 0.14 (95% CI 0.04–2.81) in imaging suspi-
cious lymph nodes. EBUS-SE scoring may thus enable a 
better prediction and separation of lymph nodes with a 
high and low probability of disease but will not replace a 
tissue diagnosis. It can, however, be a helpful tool for 
guiding which node to aspirate in a distinct region, or ul-
timately deciding whether to proceed with, or omit, ad-
ditional diagnostic procedures if ROSE or conclusive cy-
tology results are unavailable (especially when FDG-PET 
information is lacking). Yet, care needs to be taken in in-
terpreting these results. This explorative study is of lim-
ited size and further research to corroborate our findings 
using a standardized assessment procedure based on clin-
ical findings and technological considerations is recom-
mended.
Differences in EBUS-SE Scoring Methods
In the qualitative scoring, both the scoring of a major 
color component (color VAS method) and a combined 
scoring of pattern and color (modified Tsukuba score) 
perform similarly in terms of overall accuracy. Our pro-
posed use of the modified Tsukuba scoring system has 
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probability of malignancy in work-up
Fig. 4. Graphical representation of added value of performing cu-
mulative diagnostic tests in our complete dataset. The first point 
on the left at 0.375 corresponds to the prevalence of malignancy in 
our complete dataset (116 lymph nodes). FDG-PET and/or CT 
imaging is able to increase the probability of malignancy to 46% if 
found positive. Negative PET and CT imaging is able to decrease 
the probability of malignancy from 37.5 to 7.8%. After having per-
formed PET-CT imaging, EBUS-SE imaging is performed. In 
PET-CT-suspected nodes (n = 90), the probability of malignancy 
increases from 46 to 73% if EBUS-SE imaging is positive. If EBUS-
SE imaging is negative in these suspected nodes, the probability of 
malignancy decreases to 7.9%. In normal lymph node findings 
based on PET-CT imaging (n = 26), the probability of malignancy 
decreases from 7.8 to 0% if negative on EBUS-SE imaging (> 78 
strain histogram mean). However, if these lymph nodes are EBUS-
SE imaging positive (< 78 strain histogram mean), the probability 
of malignancy increases from 7.9 to 45% (online suppl. Table E.3).
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not previously been introduced in EBUS applications. 
Even though we expected that taking into account both 
pattern and color above color alone would provide more 
information, it does not seem to be of clear additional 
value over the color VAS system in this dataset.
Three studies used a scoring system like the color VAS 
scoring system, with comparable results [14, 18, 22]. He 
et al. [14] reported best accuracy if the visualized color 
was over 50% blue, then indicative of malignancy with an 
accuracy of 73.7%. Huang et al. [22] and Izumo et al. [18] 
introduced an additional cut-off; only predominantly 
blue lesions were indicative of malignancy, while pre-
dominantly non-blue lesions were indicative of benign 
lymph nodes. By leaving out an intermediary group (part 
blue, part non-blue) they were able to report an overall 
accuracy in these categories of 91.4 and 96.7%, respec-
tively. Leaving out uncertain cases (part blue, part non-
blue) was not done in our study for accurate comparison 
of scoring methods (but see online suppl. Fig. E.3, E4). 
Possibly, such a method could increase diagnostic suc-
cess.
In semiquantitative scoring, the majority of previous 
pilot studies report using the strain ratio for scoring [17, 
19, 23]. Our study, however, clearly shows that the mean 
value of the strain as obtained from the histogram has best 
performance. As reflected by the comparatively low per-
formance of the strain ratio scoring method, we found 
that the strain ratio outcome relied heavily on the selected 
secondary reference tissue region in EBUS. Adequate se-
lection of a uniform secondary reference tissue while tak-
ing into account the technical and clinical boundary con-
ditions is difficult not only because of limited tissue uni-
formity, but also heterogeneous sources of strain (online 
suppl. material). This is likely one of the reasons why oth-
er pilot studies investigating EBUS-SE with strain ratios 
reported different cut-off values [29] and collected mul-
tiple measurements for combining them into one average 
reference value [17, 19, 23]. A potential limitation of our 
study is that we collected strain ratio measurements ret-
rospectively rather than prospectively, which could have 
affected the strain ratio scoring outcome.
Combining EBUS-SE with Other Predictive Variables
FDG-PET and/or CT imaging of lymph nodes in this 
study had sensitivities comparable to the reported litera-
ture [2], but a lower combined specificity of 33% (online 
suppl. Table E.3). This could in part be explained by the 
systematic staging of all lymph nodes by EBUS-TBNA as 
applied in our clinical practice. Combining EBUS-SE 
with pre-test contrast CT and FDG-PET avidity, howev-
er, was able to improve the predictive accuracy of lymph 
node pathology in both PET-CT negative and positive 
imaging cases. The relative stiffness as measured by 
EBUS-SE thus seems to show additional value to the met-
abolic and size information as given by FDG-PET and 
CT. Yet again, care needs to be taken in interpreting the 
results of adding EBUS-SE information to PET and CT 
negative nodes, as only 26 lymph nodes, of which 2 were 
false negative, were available for an exploratory analysis. 
While adding EBUS-SE correctly changed the diagnosis 
to malignant in both cases and could be promising, ad-
ditional studies are warranted. 
Besides PET-CT information, ultrasound B-mode 
characteristics as described by Fujiwara et al. [3] were also 
collected in this explorative study (online suppl. Table 
E.1). Since different studies have shown conflicting re-
sults in the value of these features, we did not integrate 
these into a combined predictive value or integrate them 
with EBUS-SE findings [3–7]. Analysis of these features 
in our dataset showed the presence of heterogeneous 
echogenicity and a central necrosis sign to be most pre-
dictive of malignancy, with positive likelihood ratios of 
5.83 and 3.65. An AUC of 0.73 of the B-mode-based size 
of lymph nodes revealed a correlation between size and 
malignancy. 
General Remarks
The mean lymph node short axis diameter in this study 
was 9.9 mm (range 4–26). This indicates it was not a pop-
ulation with bulky mediastinal disease, but rather a group 
with a low disease burden. Malignant lymph node in-
volvement can be heterogeneous and microscopic. This 
is cause for concern in both TBNA and SE of individual 
lymph nodes. TBNA provides only limited information 
about the complete node, as it samples limited amounts 
of tissue within the node. SE can provide information 
about the entire node, but is based only on the strain of 
tissue upon deformation. Whether elastography is able to 
differentiate between micrometastatic disease accurately 
and if it may guide the site of aspiration within a lymph 
node to detect intranodal fields at risk of micrometastatic 
disease is unclear. The current dataset does not allow this 
level of analysis. 
Observer Scoring Variability
A general point of concern for all EBUS-SE measure-
ment methods is the inter- and intraobserver variability 
in lymph node scoring and frame selection through dif-
ferent platforms. System settings and operator protocol 
can affect the EBUS-SE measurement outcome (online 
Verhoeven/de Korte/van der HeijdenRespiration 2019;97:337–347346
DOI: 10.1159/000494143
suppl. material). A standardized operating procedure is 
essential. In this current study, the prospective elastogra-
phy measurements and scoring were done by one pulmo-
nologist using a standardized operating protocol 
(E.v.d.H.). Interobserver variability was thus minimal in 
order to adequately study the differences in scoring meth-
od performance. Reproducibility of this technique based 
upon operator expertise, operator color acuity, and ana-
tomical site and region needs to be further investigated. 
Widespread implementation of this technique can only 
be realized when system settings and operator methods 
are unified. Transferability of these findings to other dis-
eases, such as sarcoidosis for example, are unknown and 
also need to be studied. In doing so, we recommend using 
the mean of the strain histogram for scoring as it showed 
the best performance in this study, requires the least op-
erator input, and will have highest interobserver agree-
ment based upon technique background.
Conclusion
EBUS-SE is a sensitive technique which may help pre-
dict lymph node malignancy in patients with lung cancer. 
In this study we found that the semiquantitative mean 
histogram scoring method with a cut-off value of 78 
(range 0–255) showed the best and most reproducible 
performance in the prediction of malignancy, with 93% 
overall sensitivity, 75% specificity, 69% PPV, 95% NPV, 
and 82% accuracy. Combining the EBUS-SE mean histo-
gram scoring outcome with CT and/or PET-CT informa-
tion increased confidence in post-test probability of dis-
ease, with a positive test likelihood ratio of 4.16 (95% CI 
2.98–8.13) and a negative test likelihood ratio of 0.14 
(0.04–2.81 95% CI) in suspicious lymph nodes based on 
PET or CT imaging. We further present a standard oper-
ating procedure for EBUS-SE assessment and future re-
search.
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